NCT06462742 Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
| NCT ID | NCT06462742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese PLA General Hospital |
| Condition | Overall Survival |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2009-01-01 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2009-01-01 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are: * Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA * What is the risk factor for ablation or surgery in treating iCCA * What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.
Eligibility Criteria
Inclusion Criteria: 1. pathologically diagnosed iCCA based on the WHO classifications; 2. curative-intent liver resection or microwave ablation; 3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular/hilar invasion, extrahepatic/lymphatic metastasis or other malignancies; 4. age ≥18 years. Exclusion Criteria: Patients not meeting any one of the inclusion criteria were excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06462742 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Overall Survival. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06462742 currently recruiting?
Yes, NCT06462742 is actively recruiting participants. Contact the research team at pcpang117@163.com for enrollment information.
Where is the NCT06462742 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06462742 clinical trial?
NCT06462742 is sponsored by Chinese PLA General Hospital. The trial plans to enroll 1,000 participants.